Impact News +++ Enphase Energy Stock Slides On Q3 Earnings, Soft Outlook (Benzinga) +++ ENPHASE Aktie -3,05%

NEUROCRINE Aktie

>NEUROCRINE Aktienkurs

128.2 EUR +0.2% (Tradegate)

Ask: 128.2 EUR / 30 Stück

Bid: 125.75 EUR / 30 Stück

Tagesumsatz: 238 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

NEUROCRINE Aktie über LYNX handeln

Intraday

1 Jahr

>NEUROCRINE Performance

1 Woche: +3,1%

1 Monat: +6,1%

3 Monate: +13,4%

6 Monate: +36,0%

1 Jahr: +17,2%

laufendes Jahr: -4,7%

>NEUROCRINE Aktie

Name:

NEUROCRINE BIOSCI. DL-001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US64125C1099 / 900964

Symbol/ Ticker:

NB3 (Frankfurt) / NBIX (NASDAQ)

Kürzel:

FRA:NB3, ETR:NB3, NB3:GR, NASDAQ:NBIX

Index:

Webseite:

http://www.neurocrine.com..

Profil:

Neurocrine Biosciences Inc. is a biopharmaceutical..
>Volltext..

Marktkapitalisierung:

12282.01 Mio. EUR

Unternehmenswert:

11870.13 Mio. EUR

Umsatz:

2158.4 Mio. EUR

EBITDA:

453.71 Mio. EUR

Nettogewinn:

299.52 Mio. EUR

Gewinn je Aktie:

2.99 EUR

Schulden:

421.21 Mio. EUR

Liquide Mittel:

227.03 Mio. EUR

Operativer Cashflow:

487.85 Mio. EUR

Bargeldquote:

1.79

Umsatzwachstum:

7.68%

Gewinnwachstum:

-6.63%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

NEUROCRINE

Letzte Datenerhebung:

28.10.25

>NEUROCRINE Kennzahlen

Aktien/ Unternehmen:

Aktien: 99.18 Mio. St.

Frei handelbar: 97.29%

Leerverk. Aktien: 4.4%

Rückkaufquote: 2.69%

Mitarbeiter: 1800

Umsatz/Mitarb.: 1.13 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 20.95%

Bewertung:

KGV: 42.11

KGV lG: 31.18

KUV: 5.59

KBV: 5.24

PEG-Ratio: 17.5

EV/EBITDA: 26.16

Rentabilität:

Bruttomarge: 98.02%

Gewinnmarge: 13.88%

Operative Marge: 19.89%

Managementeffizenz:

Gesamtkaprendite: 9.68%

Eigenkaprendite: 13.39%

>NEUROCRINE Peer Group

Es sind 596 Aktien bekannt.

>NEUROCRINE Chart & Kurs - NASDAQ

>NEUROCRINE News

28.10.25 - 21:30	Neurocrine Biosciences Inc Q3 Profit Increases, Beats Estimates (AFX)
	WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc (NBIX) revealed a profit for its third quarter that Increased from the same period last year and beat the Street estimates.The company's bottom li......

28.10.25 - 21:03	Neurocrine Biosciences Reports Third Quarter 2025 Financial Results (PR Newswire)
	Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth INGREZZA® (valbenazine) Third-Quarter 2025 Net Product Sales of $687 Million Representing 12% Year-Over-Year Growth CRENESSITY® (crinecerfont) Third-Quarter 2025 Net Product Sales of $98 Million with......

24.10.25 - 19:45	Are You Looking for a Top Momentum Pick? Why Neurocrine Biosciences (NBIX) is a Great Choice (Zacks)
	Does Neurocrine Biosciences (NBIX) have what it takes to be a top stock pick for momentum investors? Let's find out....

23.10.25 - 20:30	3 Reasons Why Growth Investors Shouldn′t Overlook Neurocrine (NBIX) (Zacks)
	Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market....

21.10.25 - 17:30	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
	Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

17.10.25 - 17:18	Neurocrine Biosciences Announces Positive Data From Post-Hoc Analysis Of Tardive Dyskinesia Study (AFX)
	WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX), Friday announced a new post-hoc analysis from the Phase 3, open-label KINECT 4 study, evaluating the long-term efficacy, safety and tole......

17.10.25 - 14:33	Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules (PR Newswire)
	Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms 90% of participants who completed 48 weeks of continuous treatment with INGREZZA 40 mg achieved a ≥50% improvement in the Abnormal Involuntary......

07.10.25 - 22:03	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results (PR Newswire)
	Conference Call and Webcast Scheduled for Tuesday, October 28 SAN DIEGO, Oct. 7, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m.......

06.10.25 - 22:06	Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise (PR Newswire)
	SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neuropsychiatry franchise. Sibley, a proven leader with more than 20 years of commercial......

06.10.25 - 17:42	Neurocrine meldet starkes Umsatzwachstum für Q2 2025, Aktie gibt dennoch nach (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.10.25 - 14:33	Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington′s Disease Chorea (PR Newswire)
	Once-daily INGREZZA treatment was generally well tolerated and showed early and sustained improvements in chorea severity Findings presented at 2025 MDS International Congress of Parkinson's Disease and Movement Disorders® SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences,......

22.09.25 - 15:18	Neurocrine Reports Positive Data From Phase 2 Study Of Osavampator (AFX)
	WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX) announced the presentation of new data from the Phase 2 SAVITRI study, which showed statistically significant and clinically meaningful i......

22.09.25 - 14:33	Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder (PR Newswire)
	SAN DIEGO, Sept. 22, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 2 SAVITRI™ study, which showed statistically significant and clinically meaningful improvement in depression severity at Day 28 and Day 56 with......

16.09.25 - 22:09	Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025 (PR Newswire)
	Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024 SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster Awards SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present......

05.09.25 - 15:30	Breaking Down Neurocrine Biosciences: 12 Analysts Share Their Views (Benzinga)
	Latest Ratings for NBIX DateFirmActionFromTo Mar 2022Piper SandlerDowngradesOverweightNeutral Feb 2022Goldman SachsUpgradesNeutralBuy Feb 2022Morgan StanleyMaintainsEqual-Weight View More Analyst Ratings for NBIX View the Latest Analyst Ratings read more...

26.08.25 - 22:03	Neurocrine Biosciences to Present at Upcoming Investor Conferences in September (PR Newswire)
	SAN DIEGO, Aug. 26, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at four investor conferences in September. Chief Financial Officer Matt Abernethy, Chief Commercial Officer Eric Benevich, and Vice-President of Investor Relations Todd Tushla will......

12.08.25 - 04:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Neurocrine Biosciences im Wert von 13440281 USD (Insiderkauf)
	Gorman, Kevin Charles - Aufsichtsrat - Tag der Transaktion: 2025-08-07...

06.08.25 - 22:03	Neurocrine Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference (PR Newswire)
	SAN DIEGO, Aug. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 2025. Chief Executive Officer Kyle Gano and Vice-President of Investor Relations Todd Tushla......

05.08.25 - 07:00	Neurocrine (NBIX) Q2 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

01.08.25 - 06:48	Neurocrine (NBIX) Q2 Revenue Jumps 17% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Sich zu mühen und mit dem Widerstande zu kämpfen, ist dem Menschen Bedürfnis wie dem Maulwurf das Graben. - Arthur Schopenhauer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram